BRPI0400214A - Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro - Google Patents

Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro

Info

Publication number
BRPI0400214A
BRPI0400214A BR0400214-8A BRPI0400214A BRPI0400214A BR PI0400214 A BRPI0400214 A BR PI0400214A BR PI0400214 A BRPI0400214 A BR PI0400214A BR PI0400214 A BRPI0400214 A BR PI0400214A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
testosterone levels
applications
serum testosterone
reliable
Prior art date
Application number
BR0400214-8A
Other languages
English (en)
Inventor
Doris Huebler
Sabine Fricke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0400214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0400214A publication Critical patent/BRPI0400214A/pt
Publication of BRPI0400214A8 publication Critical patent/BRPI0400214A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSIçõES E APLICAçõES FARMACêUTICAS PARA A OBTENçãO CONFIáVEL DE NìVEIS ACEITáVEIS DE TESTOSTERONA NO SORO". A presente invenção refere-se a composições farmacêuticas formuladas para administração injetável as quais compreendem um éster de testosterona, em particular undecanoato de testosterona, em um veículo compreendendo óleo de rícino e um co-solvente. Quando de injeção das composições de acordo com um esquema de administração em particular, níveis confiáveis de testosterona no soro na faixa fisiológica normal são obtidos durante um longo período. Isso permite o uso das composições em terapia de reposição hormonal e contracepção masculina sem monitoramento concomitante dos níveis de testosterona no soro por um médico.
BRPI0400214A 2003-03-14 2004-03-15 Composições e aplicações farmacêuticas para a obtenção confiável de níveis aceitáveis de testosterona no soro BRPI0400214A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14

Publications (2)

Publication Number Publication Date
BRPI0400214A true BRPI0400214A (pt) 2005-02-09
BRPI0400214A8 BRPI0400214A8 (pt) 2023-05-09

Family

ID=32748728

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0400214A BRPI0400214A8 (pt) 2003-03-14 2004-03-15 Composições e aplicações farmacêuticas para a obtenção confiável de níveis aceitáveis de testosterona no soro
BR122017008910A BR122017008910A8 (pt) 2003-03-14 2004-03-15 Composições formuladas para injeção intramuscular e usos de um éster de testosterona

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122017008910A BR122017008910A8 (pt) 2003-03-14 2004-03-15 Composições formuladas para injeção intramuscular e usos de um éster de testosterona

Country Status (39)

Country Link
US (2) US7718640B2 (pt)
EP (2) EP1743646A3 (pt)
JP (1) JP4680891B2 (pt)
KR (2) KR20080096717A (pt)
CN (2) CN101884639A (pt)
AR (1) AR043603A1 (pt)
AT (1) ATE336251T1 (pt)
AU (1) AU2004218893B2 (pt)
BR (2) BRPI0400214A8 (pt)
CA (1) CA2518910C (pt)
CL (1) CL2004000527A1 (pt)
CO (1) CO5700724A2 (pt)
CR (1) CR7999A (pt)
CY (1) CY1105794T1 (pt)
DE (1) DE602004001893T2 (pt)
DK (1) DK1457208T3 (pt)
EA (1) EA011568B1 (pt)
EC (1) ECSP056095A (pt)
ES (1) ES2271772T3 (pt)
HR (1) HRP20050781B1 (pt)
IL (1) IL170473A (pt)
IS (1) IS2565B (pt)
JO (1) JO2505B1 (pt)
ME (2) ME00149B (pt)
MX (1) MXPA04002395A (pt)
NO (1) NO335179B1 (pt)
NZ (1) NZ542321A (pt)
PE (1) PE20041065A1 (pt)
PL (1) PL1457208T3 (pt)
PT (1) PT1457208E (pt)
RS (1) RS51537B (pt)
RU (2) RU2354381C2 (pt)
SA (1) SA04250040B1 (pt)
SI (1) SI1457208T1 (pt)
TW (1) TWI345976B (pt)
UA (1) UA82510C2 (pt)
UY (1) UY28231A1 (pt)
WO (1) WO2004080383A2 (pt)
ZA (2) ZA200508313B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
JP6457383B2 (ja) * 2012-04-06 2019-01-23 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針支援式ジェット注入投与
MA37610B1 (fr) * 2012-05-09 2017-07-31 Univ Western Health Sciences Formulations de testostérone proliposomales
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
EP4349383A3 (en) * 2013-02-11 2024-06-19 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
WO2020018974A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
US12083130B2 (en) * 2019-10-03 2024-09-10 Caren Pharmaceuticals, Inc. Combination hormone formulations and therapies
US20230227492A1 (en) * 2020-06-11 2023-07-20 The Usa As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods
KR20250176964A (ko) * 2024-06-13 2025-12-22 주식회사 종근당 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 주사용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
ME00855B (me) * 1997-12-03 2008-08-07 Merck & Co Inc Injektibilne formulacije dugog dejstva koje sadrže hidrogenisano ricinusovo ulje
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
DE69901250T2 (de) 1998-06-19 2002-10-17 Akzo Nobel N.V., Arnheim/Arnhem 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität
HU229455B1 (en) 1999-04-01 2013-12-30 Merck Sharp & Dohme Formulation comprising testosteron undecanoate and castor oil
ATE474580T1 (de) * 2000-02-15 2010-08-15 Bayer Schering Pharma Ag Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend
EP1313511B1 (en) 2000-08-23 2005-11-30 Akzo Nobel N.V. Testosterone ester formulation for human use

Also Published As

Publication number Publication date
RU2005131724A (ru) 2006-05-10
MEP14508A (en) 2010-06-10
PT1457208E (pt) 2007-01-31
KR20080096717A (ko) 2008-10-31
NO335179B1 (no) 2014-10-13
PL1457208T3 (pl) 2007-01-31
NO20054711D0 (no) 2005-10-13
JO2505B1 (en) 2009-10-05
US20050032762A1 (en) 2005-02-10
CN1761469A (zh) 2006-04-19
RU2354381C2 (ru) 2009-05-10
BR122017008910A2 (pt) 2005-02-09
HK1069325A1 (en) 2005-05-20
BRPI0400214A8 (pt) 2023-05-09
WO2004080383B1 (en) 2005-05-06
JP4680891B2 (ja) 2011-05-11
CO5700724A2 (es) 2006-11-30
EP1457208B9 (en) 2006-10-25
HRP20050781B1 (hr) 2015-04-10
CA2518910A1 (en) 2004-09-23
SA04250040B1 (ar) 2008-01-07
CL2004000527A1 (es) 2005-02-18
EP1743646A3 (en) 2007-03-28
DE602004001893D1 (de) 2006-09-28
EP1743646A2 (en) 2007-01-17
NZ542321A (en) 2008-05-30
ECSP056095A (es) 2006-03-01
BR122017008910A8 (pt) 2023-05-09
ES2271772T3 (es) 2007-04-16
EA011568B1 (ru) 2009-04-28
AU2004218893B2 (en) 2008-10-09
US8338395B2 (en) 2012-12-25
WO2004080383A2 (en) 2004-09-23
RS51537B (sr) 2011-06-30
TW200511997A (en) 2005-04-01
RU2007118196A (ru) 2008-11-27
HRP20050781A2 (en) 2005-10-31
CA2518910C (en) 2009-09-08
IL170473A (en) 2010-05-31
WO2004080383A3 (en) 2005-03-31
EP1457208A1 (en) 2004-09-15
ATE336251T1 (de) 2006-09-15
US20090156564A1 (en) 2009-06-18
RS20050702A (sr) 2007-06-04
TWI345976B (en) 2011-08-01
CR7999A (es) 2006-05-29
AR043603A1 (es) 2005-08-03
EA200501819A1 (ru) 2006-06-30
MXPA04002395A (es) 2004-09-20
SI1457208T1 (sl) 2007-02-28
US7718640B2 (en) 2010-05-18
NO20054711L (no) 2005-12-13
ME00149B (me) 2010-06-10
ZA200700046B (en) 2008-04-30
IS8069A (is) 2005-10-12
CY1105794T1 (el) 2011-02-02
DK1457208T3 (da) 2006-12-11
EP1457208B1 (en) 2006-08-16
CN1761469B (zh) 2019-05-17
CN101884639A (zh) 2010-11-17
UY28231A1 (es) 2004-11-08
IS2565B (is) 2009-12-15
KR20050109561A (ko) 2005-11-21
UA82510C2 (uk) 2008-04-25
DE602004001893T2 (de) 2007-03-15
ZA200508313B (en) 2007-04-25
PE20041065A1 (es) 2005-02-24
KR100882378B1 (ko) 2009-02-05
JP2006520377A (ja) 2006-09-07
AU2004218893A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
BRPI0400214A (pt) Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
AU7315301A (en) Compounds and compositions for delivering active agents
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0012696A (pt) Composição oftálmica
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
ES2150404T1 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
DE50311479D1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
ATE218366T1 (de) Pharmazeutische zusammensetzung enthaltend factor xiiia für nervenheilung
ECSP003689A (es) Uso de (+)- tramadol, o- demetiltramadol y/o (+)- o- demetiltramadol, o-desmetil-n-monodesmetil-tramadol, particularmente (+) -o- desmetil-n-monodesmetil-tramadol para la preparacion de un medicamento para el tratamiento de urgencia urinaria incremen
BRPI0500420A (pt) composição estável para substáncia farmacologicamente ativa

Legal Events

Date Code Title Description
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 1779 DE 09/02/2005, QUANTO AO ITEM (72); CONFORME SOLICITADO NA PETICAO NO 020050006885/RJ DE 31/01/2005.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application

Free format text: INPI NO 52402.010957/2021-78 ORIGEM: JUIZO FEDERAL DA 25A VF DO RIO DE JANEIRO (TRF2 PROCESSO NO: 5101499-35.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO AUTOR: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B25A Requested transfer of rights approved

Owner name: GRUENENTHAL GMBH (DE)

B15N Others concerning applications: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.010957/2021-78 25A VARA FEDERAL DO RIO DE JANEIRO PROCEDIMENTO COMUM NO 5101499-35.2021.4.02.5101/RJ AUTOR: GRUENENTHAL GMBH REU: INPI-INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL SENTENCA: ANTE O EXPOSTO, HOMOLOGO A RENUNCIA AO DIREITO SOBRE O QUAL SE FUNDA A ACAO E JULGO EXTINTO O PROCESSO, COM RESOLUCAO DO MERITO, COM FULCRO NO ARTIGO 487, INCISO III, ALINEA "C", DO CODIGO DE PROCESSO CIVIL. TRANSITADA EM JULGADO.